Search

Your search keyword '"Bensussan, Armand"' showing total 1,289 results

Search Constraints

Start Over You searched for: Author "Bensussan, Armand" Remove constraint Author: "Bensussan, Armand"
1,289 results on '"Bensussan, Armand"'

Search Results

1. Early elevated IFNα is a key mediator of HIV pathogenesis

5. Coencapsulation of Immunosuppressive Drug with Anti-Inflammatory Molecule in Pickering Emulsions as an Innovative Therapeutic Approach for Inflammatory Dermatoses

7. Targeting TGF-beta activation in cutaneous T-cell lymphomas

8. “Co-encapsulation of Immunosuppressive Drug with Anti-inflammatory Molecule in Pickering Emulsions as a Novel Therapeutic Approach for Inflammatory Dermatoses”

11. ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells

12. The HLA-B*57:01 allele corresponds to a very large MHC haploblock likely explaining its massive effect for HIV-1 elite control

13. Microenvironment tailors nTreg structure and function

15. CD160

16. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial

17. Syndrome de Sézary.

18. CD38 targeting in aggressive, treatment-refractory cutaneous T-cell lymphomas

22. Early Elevated IFNα Identified as the Key Mediator of HIV Pathogenesis and its low level a Hallmark of Elite Controllers

23. IFNα induces CCR5 in CD4+ T-cells, causing its anti- HIV inefficiency and its subsequent pathogenic elevation, partially controlled by anti-HIV therapy

25. Abstract 710: Preclinical development of ALD2510, a Next-Gen Fc-enhanced, TREG-selective and IL-2-sparing anti-CD25 antibody for the treatment of solid tumors

26. Abstract 464: AAC-11 survival pathways as therapeutic target in cancer: AAC-11 leucine-zipper domain derived peptides exert potent antitumor effects and exhibit favorable stability, pharmacokinetic and toxicology profiles

28. Data from Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity

29. Supplementary Figure 1 from Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity

30. Supplementary Figure 4 from Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity

31. Supplementary Material and Methods; Figure Legends from Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity

32. Supplementary Figure 5 from Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity

33. Supplementary Figure 2 from Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity

34. Supplementary Figure 3 from Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity

39. CD38 targeting in aggressive, treatment-refractory cutaneous T-cell lymphomas

43. Fc receptors act as innate immune receptors during infection?

45. CD24hiCD27+ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease

47. Biological Characterization and Differential Gene Expression Analysis of CYT-338 NK Cell Engager (NKE) Against CD38 Expressing Tumors Including Multiple Myeloma (MM)

49. 1339 ALD2510: next generation Fc-enhanced, TREG-selective and IL-2-sparing anti-CD25 antibody with promising potential for the treatment of gynecological cancers

Catalog

Books, media, physical & digital resources